[go: up one dir, main page]

WO2009002811A3 - Therapeutic platelet compositions and methods - Google Patents

Therapeutic platelet compositions and methods Download PDF

Info

Publication number
WO2009002811A3
WO2009002811A3 PCT/US2008/067592 US2008067592W WO2009002811A3 WO 2009002811 A3 WO2009002811 A3 WO 2009002811A3 US 2008067592 W US2008067592 W US 2008067592W WO 2009002811 A3 WO2009002811 A3 WO 2009002811A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
angiogenesis
platelets
regulating
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/067592
Other languages
French (fr)
Other versions
WO2009002811A2 (en
Inventor
Dennis Orgill
Giorgio Pietramaggiori
Giannoula Klement
David Cervi
Judah Folkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Original Assignee
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Boston Childrens Hospital filed Critical Brigham and Womens Hospital Inc
Publication of WO2009002811A2 publication Critical patent/WO2009002811A2/en
Publication of WO2009002811A3 publication Critical patent/WO2009002811A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are methods and compositions for the therapeutic delivery of angiogenesis-regulating factors to in vivo sites in need thereof. The methods and compositions relate generally to the use of platelets bearing one or more exogenous angiogenesis regulating factors. In one aspect, described are methods of delivering an angiogenesis-regulating factor, the method comprising contacting a tissue with a composition comprising isolated platelets comprising an exogenous angiogenesis regulating factor. The methods can be employed for example, to enhance wound healing, or alternatively, to inhibit tumor growth. In another aspect, therapeutic platelet compositions and kits are provided in which the platelets bear one or more exogenous angiogenesis regulating factors. Also provided are methods of modulating the release angiogenesis promoting and inhibiting factors by platelets using agonists and/or antagonists of platelet protease-activated receptors PAR-1 and PAR-4.
PCT/US2008/067592 2007-06-22 2008-06-20 Therapeutic platelet compositions and methods Ceased WO2009002811A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93692107P 2007-06-22 2007-06-22
US60/936,921 2007-06-22

Publications (2)

Publication Number Publication Date
WO2009002811A2 WO2009002811A2 (en) 2008-12-31
WO2009002811A3 true WO2009002811A3 (en) 2009-02-12

Family

ID=39930521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067592 Ceased WO2009002811A2 (en) 2007-06-22 2008-06-20 Therapeutic platelet compositions and methods

Country Status (1)

Country Link
WO (1) WO2009002811A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3095856T3 (en) 2008-09-16 2019-10-21 Mayo Found Medical Education & Res COMPOSITIONS WITH TROMBOCYTIC CONTENTS
US20150250822A1 (en) * 2012-10-04 2015-09-10 Genesys Research Institute Platelet compositions and uses thereof
WO2015109220A1 (en) * 2014-01-17 2015-07-23 President And Fellows Of Harvard College Platelet decoy and use thereof
WO2015124570A1 (en) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
CA2949225A1 (en) 2014-05-16 2015-11-19 Mayo Foundation For Medical Education And Research Cell culture media compositions for primary cells
BR112020013656A2 (en) 2018-01-05 2020-12-01 Platelet Biogenesis, Inc. compositions and methods for producing megakaryocytes
JP2021529770A (en) 2018-06-29 2021-11-04 プレートレット バイオジェネシス， インコーポレイテッド Compositions for drug delivery and how to use them
TWI827321B (en) * 2020-03-20 2023-12-21 台灣粒線體應用技術股份有限公司 Composition containing mitochondria and its use as a collagen proliferation promoter
WO2021231990A1 (en) * 2020-05-15 2021-11-18 Platelet Biogenesis, Inc. Improved methods and production of novel platelets
CN119139532A (en) * 2024-11-20 2024-12-17 昆明医科大学 Sponge patch and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066923A1 (en) * 1998-06-22 1999-12-29 Autologous Wound Therapy, Inc. Application for utility patent for improved enriched platelet wound healant
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066923A1 (en) * 1998-06-22 1999-12-29 Autologous Wound Therapy, Inc. Application for utility patent for improved enriched platelet wound healant
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ITALIANO JOSEPH ET AL: "Blood platelets organize pro- and anti-angiogenic factors into separate, distinct alpha granules: Implications for the regulation of angiogenesis", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, 16 November 2006 (2006-11-16), pages 120A - 121A(Abst, XP009108492, ISSN: 0006-4971 *
MA L. ET AL.: "Proteinase-activated recepors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.", PNAS, vol. 102, no. 1, 4 January 2005 (2005-01-04), pages 216 - 220, XP002503736 *
PIETRAMAGGIORI G.: "Trehalose lyophilized platelets for wound healing.", WOUND REP. REG., vol. 15, April 2007 (2007-04-01), pages 213 - 220, XP002503737 *
SALGADO R ET AL: "Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study", ANGIOGENESIS, KLUWER, DORDRECHT, NL, vol. 4, 1 January 2001 (2001-01-01), pages 37 - 43, XP002995368, ISSN: 0969-6970 *

Also Published As

Publication number Publication date
WO2009002811A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2009002811A3 (en) Therapeutic platelet compositions and methods
WO2014040074A3 (en) Compositions and methods for treating cutaneous scarring
MX2009010067A (en) Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors.
WO2009149418A3 (en) Compositions for the in vivo delivery of rnai agents
WO2010003120A3 (en) Antagonists of prostaglandin d2 receptors
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2009097508A3 (en) Methods and compositions for wound healing
WO2012064697A3 (en) Materials presenting notch signaling molecules to control cell behavior
WO2008115974A3 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2009108934A3 (en) Injectable calcium phosphate cememts formulated with bioactive agents and methods for making same
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
ATE545441T1 (en) METHOD AND DEVICE FOR THE MINIMALLY INVASIVE DELIVERY OF CELL-CONTAINING FLOWABLE COMPOSITIONS
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2007112084A8 (en) Method to modulate hematopoietic stem cell growth
WO2010111502A3 (en) Medical devices with galvanic particulates
WO2012058673A3 (en) Enhanced cancer treatment and monitoring using recombinant vectors
WO2007038246A3 (en) Solid polymer delivery compositions and methods for use thereof
WO2010078538A3 (en) Enhanced carriers for the delivery of microparticles to bodily tissues and fluids
WO2009140642A3 (en) Tricyclic antagonists of prostaglandin d2 receptors
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
CL2009000246A1 (en) Compounds derived from 1h-imidazo [4,5-b] pyridin-2-ol; modulators of sarcomero contraction; pharmaceutical composition comprising; pharmaceutical kit; and use in the treatment of neuromuscular diseases, such as atrophy, fatigue, claudication, among others.
WO2010028254A3 (en) Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
EP4467160A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
MX2021013582A (en) Compositions comprising biologically active agents and bile salts.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771541

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08771541

Country of ref document: EP

Kind code of ref document: A2